[1] Swain MG,Lai MY,Shiffman ML,et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gastroenterology, 2010,139（5）:1593-1601.
[2] Morgan TR,Ghany MG,Kim HY,et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology,2010,52（3）:833-844.
[3] Veldt BJ,Heathcote EJ,Wedemeyer H,et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med,2007,147（10）:677-684.
[4] Backus LI,Boothroyd DB,Phillips BR,et al. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol,2011,9（6）:509-516.
[5] Zeuzem S,Andreone P,Pol S,et al. Telaprevir for retreatment of HCV infection. N Engl J Med,2011,364（25）:2417-2428
[6] Foster GR,Zeuzem S,Andreone P,et al. Subanalyses of the telaprevir lead-in arm in the realize study:response at week 4 is not a substitute for prior null response categorization. J Hepatol,2011,54（Suppl 1）:S3.
[7] Ghany MG,Nelson DR,Strader DB,et al. An update on treatment of genotype 1 chronic hepatitis C virus infection:2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology,2011,54（4）:1433-1444.
[8] Duarte-Rojo A,Heathcote EJ,Feld JJ. 'Easy to treat' genotypes were not created equal: can rapid virological response （RVR） level the playing field?J Hepatol,2011,55（2）:466-473.
[9] Andriulli A,Mangia A,Iacobellis A,et al. Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther,2008,28（4）:397-404.
[10] Mangia A,Bandiera F,Montalto G,et al. Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3. J Hepatol,2010,53（6）:1000-1005.
[11] European Association for the Study of the Liver. EASL Clinical Practice Guidelines:management of hepatitis C virus infection. J Hepatol,2011,55（2）:245-264.
[12] Ank N,Iversen MB. An important role for type III interferon （IFN-{lambda}/IL-28）in TLR-induced antiviral activity. J Immunol,2008,180（4）:2474-2485.
[13] Marcello T,Grakoui A,Barba-Spaeth G,et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology,2006,131（6）:1887-1898.
[14] Tillmann HL,Thompson AJ,Patel K,et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology,2010,139（5）:1586-1592.
[15] Thomas DL,Thio CL,Martin MP,et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature, 2009,461（7265）:798-801.
[16] Liao XW,Ling Y,Li XH,et al. Association of genetic variation in IL28B with hepatitis C treatment-induced viral clearance in the Chinese Han population. Antivir Ther,2011,16（2）:141-147.
[17] Thompson AJ,Muir AJ,Sulkowski MS,et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology,2010,139（1）:120-129.
[18] Poordad F,Bronowicki JP,Gordon SC,et al. IL28B polymorphism predicts virologic response in patients with hepatitis c genotype 1 treated with boceprevir（boc）combination therapy. J Hepatol,2011,54（Suppl 1）:S6.
[19] Marcellin P,Heathcote EJ,Craxì A. Which patients with genotype 1 chronic hepatitis C can benefit from prolonged treatment with the 'accordion' regimen?J Hepatol,2007,47（4）:580-587.
[20] Reau N,Satoskar R,Te H,et al. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C. Am J Gastroenterol,2011,106（3）:452-458. [21] McHutchison JG,Lawitz EJ,Shiffman ML,et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med,2009,361:580-593.
[22] Awad T,Thorlund K,Hauser G,et al. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C:systematic review of randomized trials. Hepatology,2010,51:1176-1184.
[23] http://www.clinicaloptions.com/inPractice/Hepatology/Hepatology/ch8_Mgmt_of_He... 2012-06-14.
[24] Chevaliez S,Hézode C,Soulier A,et al. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype（SYREN trial）. Gastroenterology,2011,141（1）:119-127.
[25] Shiffman ML,Ghany MG,Morgan TR,et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology,2007,132（1）:103-112.
[26] Diago M,Shiffman ML,Bronowicki JP,et al. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a（40 kDa）plus ribavirin. Hepatology,2010,51（6）:1897-1903. |
